Vivus Inc. (NASDAQ:VVUS) is a biotechnology company that has received approval for their two drugs Qsymia (for weight loss) and Stendra (for erectile dysfunction). On last trading day VIVUS, Inc. (NASDAQ:VVUS) ended up 2.01%higher to close at $6.10 while trading in the range of $5.85 – $6.14. Its return on assets (ROA) is -46.80% while return on investment (ROI) is -42.20%.VIVUS, Inc. (NASDAQ:VVUS) monthly performance is -5.86%.
Arena Pharmaceuticals (NASDAQ:ARNA) was the recipient of unusually large options trading activity on Monday. Stock investors purchased 4,297 put options on the company, Analyst Ratings News reports. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) in last trading activity ended up at $6.98 with day range of $6.90 – $7.14. Company weekly performance is 2.65% while its quarterly performance stands at 12.58%.Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is -24.54% away from its 52 week high.
The company on Feb. 25 reported financial results for the fourth quarter and full year ended December 31, 2013 and provided an update on corporate developments. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) belongs to Healthcare sector with market capitalization of 1.44 billion and has 1.70% insider ownership. In last trading activity company’s stock closed at $7.78 while opening price was 8.07.
MannKind (NASDAQ:MNKD) was the recipient of some unusual options trading on Thursday. Stock traders purchased 14,654 put options on the stock, AmericanBankingNews.com reports. This is an increase of 113% compared to the typical daily volume of 6,888 put options. On Monday shares of MannKind Corporation (NASDAQ:MNKD) opened at $5.69 and closed at $5.71. This Year Company’s Earnings per Share (EPS) growth is -0.59 and next year’s estimated EPS growth is 41.90%. Analysts mean target price for MannKind Corporation (NASDAQ:MNKD) is 7.21.